Rigel's Q2 results highlight soaring revenue and raised guidance for 2025. See more on RIGL stock's growth potential, ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the top most undervalued biotech stocks to buy now. On August 6, analyst ...

Rigel’s shares had dropped 74% this year, but had rebounded 40% by late Friday morning. Just 10 days ago, the company received a letter from Nasdaq notifying the company that it did not meet its ...

Q2 2025 Management View Raul R. Rodriguez, President and CEO, stated that "this was a really great quarter for Rigel" and highlighted net product sales of more than $58 million, marking a 76% increase ...

Rigel Pharmaceuticals Inc (RIGL) reports a 76% increase in net product sales and raises 2025 revenue guidance, signaling ...

Rigel Pharmaceuticals (RIGL) could be a solid addition to your portfolio given a notable revision in the company's earnings ...

Rigel Pharmaceuticals Annual EPS Estimates (Seeking Alpha) As for the annual EPS, we can see that the Street has Rigel’s earnings rising through 2030, going from -0.38 for 2024 to 2.18 for 2030.

Rigel Pharmaceuticals had a net margin of 2.46% and a negative return on equity of 14.80%. Sell-side analysts expect that Rigel Pharmaceuticals will post 0.22 EPS for the current fiscal year.

From a technical perspective, Rigel Pharmaceuticals, Inc. (RIGL) is looking like an interesting pick, as it just reached a ...

Rigel is a blue supergiant that is the brightest star in the constellation Orion (the Hunter). Due to its measured size and brightness it is expected to end in a supernova one day. It also has two ...